• 1. Emerging investigators
  Polym. Chem., 2015,6, 5501-5502
• 2. Dissolved oxygen sensor based on fluorescence quenching of oxygen-sensitive ruthenium complexes immobilized in sol–gel-derived porous silica coatings
  Analyst, 1996,121, 785-788
• 3. Ester-mediated peptide formation promoted by deep eutectic solvents: a facile pathway to proto-peptides?
  Chen-Yu Chien,Sheng-Sheng Yu Chem. Commun., 2020,56, 11949-11952
• 4. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?
  Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245
• 5. Examination of the hydrogen-bonding networks in small water clusters (n = 2–5, 13, 17) using absolutely localized molecular orbital energy decomposition analysis?
  Erika A. Cobar,Paul R. Horn,Robert G. Bergman,Martin Head-Gordon Phys. Chem. Chem. Phys., 2012,14, 15328-15339

• Solvents and Organic Chemicals Organic Compounds Organic acids and derivatives Carboxylic acids and derivatives Amino acids, peptides, and analogues Amino acids and derivatives

Recent Advances in the Study of 3-amino-3-cyclohexylbutanoic acid (CAS: 1270444-33-1)

3-amino-3-cyclohexylbutanoic acid (CAS: 1270444-33-1) is a chiral β-amino acid derivative that has garnered significant attention in the field of chemical biology and pharmaceutical research. Its unique structural features, including a cyclohexyl ring and an amino group at the β-position, make it a valuable building block for the synthesis of bioactive molecules and potential drug candidates. Recent studies have explored its applications in medicinal chemistry, particularly in the development of enzyme inhibitors and peptidomimetics.

One of the key areas of research involving 3-amino-3-cyclohexylbutanoic acid is its role as a scaffold for designing γ-aminobutyric acid (GABA) analogs. GABA is the primary inhibitory neurotransmitter in the central nervous system, and its analogs have been investigated for their potential in treating neurological disorders such as epilepsy, anxiety, and chronic pain. The cyclohexyl moiety in 3-amino-3-cyclohexylbutanoic acid provides enhanced lipophilicity and metabolic stability, which are critical for improving the pharmacokinetic properties of GABAergic drugs.

Recent synthetic methodologies have focused on optimizing the enantioselective synthesis of 3-amino-3-cyclohexylbutanoic acid to obtain high-purity enantiomers. Asymmetric hydrogenation and enzymatic resolution techniques have been employed to achieve this goal. For instance, a 2023 study published in the Journal of Organic Chemistry demonstrated a novel catalytic system for the asymmetric hydrogenation of β-enamido esters, yielding 3-amino-3-cyclohexylbutanoic acid with excellent enantiomeric excess (ee > 99%). This advancement is expected to facilitate the large-scale production of the compound for preclinical and clinical studies.

In addition to its applications in neuroscience, 3-amino-3-cyclohexylbutanoic acid has shown promise in the design of protease inhibitors. A recent study highlighted its incorporation into peptidomimetic structures targeting HIV-1 protease, where the cyclohexyl group was found to enhance binding affinity and selectivity. Molecular docking simulations and X-ray crystallography data revealed that the compound's rigid cyclohexyl ring effectively occupies the hydrophobic pockets of the protease active site, thereby inhibiting viral replication.

Another emerging application of 3-amino-3-cyclohexylbutanoic acid is in the field of antibiotic development. Researchers have explored its potential as a precursor for β-lactamase inhibitors, which are critical for overcoming bacterial resistance to β-lactam antibiotics. Preliminary in vitro assays have demonstrated that derivatives of 3-amino-3-cyclohexylbutanoic acid exhibit potent inhibitory activity against extended-spectrum β-lactamases (ESBLs), a major concern in hospital-acquired infections.

Despite these promising developments, challenges remain in the clinical translation of 3-amino-3-cyclohexylbutanoic acid-based therapeutics. Issues such as bioavailability, toxicity, and off-target effects need to be addressed through rigorous preclinical testing. Future research directions may include the development of prodrug strategies to improve oral absorption and the exploration of novel formulations to enhance delivery to target tissues.

In conclusion, 3-amino-3-cyclohexylbutanoic acid (CAS: 1270444-33-1) represents a versatile and pharmacologically relevant scaffold with broad applications in drug discovery. Recent advances in its synthesis and functionalization have opened new avenues for the development of therapeutics targeting neurological disorders, infectious diseases, and beyond. Continued interdisciplinary collaboration between chemists, biologists, and pharmacologists will be essential to fully realize its potential in the pharmaceutical industry.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)